News

Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.

A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.

In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.

Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.

Women with ovarian cancer who received 2 years of maintenance therapy with olaparib experienced a 45% reduction in risk of death, according to a 7-year follow-up.

Seon Jo Park, PharmD, BCOP and Heather Kennihan, MSN, RN, OCN, discuss the best practices that their institution uses to ensure the safe handling of immunotherapy.

Pegfilgrastim-fpgk, a biosimilar medicine of pegfilgrastim, has received FDA approval for patients with non-myeloid malignancies and a clinically significant incidence of febrile neutropenia.

Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.

Spoon theory can help patients with cancer learn to measure and conserve their energy.

Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.

The results of the phase 3 MASTERKEY-265 trial show that there is still an unmet need for patients who are refractory to pembrolizumab and anti–PD-1 inhibitors.

The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.

Phase 2 findings from the CADENZA trial suggest that pivekimab sunirine may be effective against blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of hematologic cancer.

Compared with gefitinib monotherapy, a combo regimen of gefitinib plus chemotherapy generated superior time to second progression in untreated non–small cell lung cancer.

At a median follow-up of 22.9 months, patients with platinum-refractory metastatic urothelial carcinoma achieved a median overall survival of 14.6 months with EphB4-human serum albumin plus pembrolizumab.

Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.

The FDA has approved durvalumab for patients with advanced or metastatic biliary tract cancers. The immunotherapy comes with warnings for immune-related adverse events and infusion reactions.

Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.

Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.

There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2022.

A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.

Younger women who underwent endoscopies had a reduced risk of colorectal cancer incidence, according to findings of a prospective cohort study.

An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.

Starting patients with unresectable or metastatic renal cell carcinoma on a reduced dose of VEGF tyrosine kinase inhibitor (TKI) therapy did not compromise survival outcomes.

A combination of niraparib plus ipilimumab were associated with a 6-month PFS rate of 59.6%, whereas a combination of nivolumab plus the PARP inhibitor yielded a rate of 20.6%.

Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.

Pemigatinib has received FDA approval for relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement. Patients receiving pemigatinib will require monitoring for ocular toxicities and high phosphate levels.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.